C ell therapy has emerged as a promising option to treat myocardial infarction or heart failure; more than 1500 patients with cardiovascular diseases are treated with adult progenitor cells worldwide. The treatment of acute and chronic myocardial infarction with adult bone marrowderived cells provided a modest benefit in most but not all studies. A number of plausible reasons have been discussed to explain the modest effects, sending researchers back to the bench to elucidate strategies to overcome the limitations of cell therapy and to develop more efficient approaches. Such strategies include the use of other sources to isolate adult progenitor cells (eg, adipose or cardiac tissue) or the generation of pluripotent cells by the reprogramming of somatic cell types. Successful cardiac cell therapy in clinical practice also depends on the efficient delivery and the appropriate integration and alignment of injected or infused cells. The pretreatment of cells with activators to augment cell homing and survival or the improvement of cell delivery tools may provide an opportunity to increase the number of active cells in ischemic or diseased tissues, thereby increasing their therapeutic potential. Finally, the identification of molecules guiding cardiac differentiation provides novel tools to enforce the formation of new functionally active cardiomyocytes to augment cardiac regeneration in its pure sense.
Selecting Subtypes of Cells
This section provides a short overview of the different cell types that have been or are currently being tested for the treatment of patients with acute myocardial infarction or chronic heart failure ( Figure 1 ). Most of the clinical studies performed so far have used bone marrow-derived mononuclear cells (BMCs) for treating patients with acute or chronic infarcts (for review, see elsewhere 1 ). Overall, a modest but significant benefit was seen in meta-analyses of all published studies. 2, 3 Particularly in the acute setting, the infusion of BMCs via balloon catheters into the infarct artery led to a 3% to 4% increase in left ventricular ejection fraction and reduced volume expansion beyond that provided by state-ofthe-art interventional and/or pharmacological therapy as outlined in recent meta-analyses. 2, 3 If these results could be confirmed in larger-scale clinical trials, even the modestly improved ejection fraction by cell therapy in addition to current state-of-the art therapy appears promising, given that an improvement in left ventricular ejection fraction of Ϸ4% observed in patients with late reperfusion therapy after acute myocardial infarction conferred a survival benefit. 4 However, for regeneration therapy, researchers and clinicians have been expecting a more profound effect. Besides the use of total BMCs, the selection of cells with antibodies directed against surface markers was suggested to enrich therapeutically active cells. Several studies selected CD34 ϩ 5 or CD133 ϩ 6 hematopoietic progenitor cells (which make up endothelial progenitor cells [EPCs] ); a recent study additionally isolated cells that coexpress CD34 and the chemokine receptor CXCR4 (Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction [REGENT] trial 7 ). Other studies are using cultured mesenchymal stem cells (MSCs) (Prospective randomized study of mesenchymal stem cell therapy in patients undergoing cardiac surgery [PROMETHEUS trial]; www.clinicaltrials.org/NCT00587990). So far, the clinical improvement seen in these pilot studies with isolated hematopoietic/EPCs appears similar to that obtained with treatment with total BMCs 7 ; however, several larger-scale trials are ongoing.
Besides developing cell enhancement strategies for bone marrow-derived cells, one may consider using cells from other sources. The adipose tissue, which can be easily harvested by liposuction, is a rich source for multipotent hematopoietic, endothelial, but also mesenchymal progenitor cells. Experimental data showed that these adipose tissuederived stromal cells augment neovascularization and improve functional recovery after ischemia, at least to an extent similar to that of their bone marrow counterparts (for review, see elsewhere 8 Of note, multiple other (stem) cell types are currently being experimentally tested. Embryonic stem cells (ESCs) were among the most promising candidates for generating cardiac tissue, although ethical issues, immune tolerance, and teratoma formation are imposing challenges for using ESC as therapy (for review, see the work by Freund and Mummery 11 ). The generation of patient-specific pluripotent stem cells by nuclear reprogramming of somatic cells by pluripotency genes provides an exciting new perspective. Reprogramming of murine fibroblasts by the combination of OCT3/4, SOX2, KLF4, and c-MYC was recently shown to generate pluripotent stem cells capable of postischemic contractile performance and in situ regeneration of cardiac, smooth muscle, and endothelial tissue in mouse models. 12 Thus, derivatives of pluripotent stem cells might be attractive for treating cardiac diseases, although specific additional challenges have been identified that preclude short-term application in clinical cell therapy. 11
Enhancement Strategies
Here, a number of plausible reasons are discussed to explain the modest effects of cell therapy achieved so far. First, it has been demonstrated that the functional activity of bone marrow-derived cells is impaired, particularly in heart failure patients. This is of major concern when the patient's own cells are used for autologous cell therapy. Allogeneic cells may be an alternative; however, this imposes additional safety concerns regarding the rejection of the transplanted cells. Second, the engraftment of the injected cells in experimental studies and the short-term homing in patients undergoing cell therapy with labeled cells are rather low (reviewed elsewhere 13, 14 ). Third, it has been questioned whether bone marrow-derived subsets of cells can differentiate to cardiomyocytes, leading to the formation of new contractile mass. All of these limitations sent researchers back to the bench to develop strategies to improve cell engraftment and survival by enforcing differentiation, as discussed below.
Strategies to Improve the Functional Activity of Patient-Derived Cells
Because bone marrow-derived or circulating cells isolated in patients with risk factors for coronary artery disease or heart failure exhibit a reduced capacity to augment neovascularization after ischemia in animal models, several studies were aimed at rescuing the defective properties of these cells. HMG-CoA reductase inhibitors, statins, were first reported to increase the number of EPCs in patients and in experimental models. 15, 16 In addition to the systemic effects, statins directly augmented the migratory capacity and improved the survival of EPCs in vitro, and prestimulation of EPCs with statins increased their neovascularization-promoting effect. The mechanisms by which statins affect the in vitro functions of EPCs are not entirely clear but may involve the activation of PI3 kinase and Akt and subsequent activation of the endothelial nitric oxide (NO) synthase. 16, 17 Because NO bioavailability is reduced in patients with coronary artery disease but required for progenitor cell-mediated neovascularization, 18, 19 it is not surprising that increasing NO synthesis and bioactivity improves progenitor cell functions.
The NO system can be activated by compounds that transcriptionally enhance endothelial NO synthase expression in hematopoietic cells and EPCs. 20 The pretreatment of cells from patients with heart failure with these endothelial NO synthase-enhancing drugs improved the functional activity and partially rescued the impairment of the cell function. 20 Moreover, ex vivo pretreatment of mesoangioblasts with NO donors augmented the efficacy of cell therapy of muscular dystrophies, 21 and oral treatment with HCT 1026, a substance that releases NO and exhibits a nonsteroidal antiinflammatory activity, enhances the uptake of intravenously delivered stem cells in muscular dystrophies Ϸ4-fold. 22 Other possibilities to augment endothelial NO synthase expression and activity include the use of peroxisome proliferator-activated receptor-␥ agonists or systemic application of estrogen. [23] [24] [25] Verma et al 23 demonstrated that peroxisome proliferator-activated receptor-␥ agonists prevented the suppression of EPC function by C-reactive protein in vitro. The peroxisome proliferator-activated receptor-␥ agonist rosiglitazone recently was shown to consistently restore dysfunctional EPCs from diabetic patients and to improve the survival and the endothelium-regenerating activities of infused progenitor cells. 26 Of particular benefit in patient-derived cells might be the blockade of kinases, which are upregulated during disease, such as the mitogen-activated protein kinase p38. Pharmacological inhibitors of p38 indeed improved peripheral blood-derived cells isolated from patients with diabetes and cardiovascular diseases. 27 Aging and cellular senescence contribute to progenitor cell dysfunction, 28 and statins have been shown to at least partially antagonize progenitor cell senescence via activation of the PI3 kinase/Akt pathway. 29 Statin treatment further augmented the expression of telomere repeat-binding factor-2, thereby counteracting telomere dysfunction. 30 Current evidence also demonstrates that age-dependent impairment of EPCs is corrected by growth hormone-mediated increase of insulin-like growth factor 1 (IGF-1). 31 Modulation of the growth hormone and IGF-1 system may therefore be useful in future regenerative cell-based therapies. In addition, age-related dysfunctions might be corrected by overexpression of the telomerase subunit telomerase reverse transcriptase, which significantly enhanced EPC-mediated limb perfusion. 32, 33 
Strategies to Augment Homing, Survival, and Engraftment
The low rate of cell homing, retention, and survival is one of the major limitations in current experimental and clinical studies with all different types of cells available. Particularly after intracoronary cell delivery, cells need to extravasate and transmigrate into the target tissue ( Figure 2 ). Direct injection of the cells into the myocardium or by perivascular delivery may provide an advantage in this respect, but even after local injection, survival and long-term engraftment were rather modest (reviewed elsewhere 14 ) . The understanding of homing mechanisms and tools to improve survival and retention is therefore of crucial importance for regenerative therapies ( Figure 2 ). Basically, 2 strategies might be used to augment cell engraftment. First, one may consider pretreating the cells to stimulate adhesion, migration, survival, or differentiation. Second, pretreatment of the target tissue to provide the appropriate milieu for progenitor cell recruitment, long-term engraftment, and differentiation might be an option, particularly when cells are delivered to patients with chronic heart failure and established scars in whom homing was shown to be extremely poor. 34 Various experimental studies addressed this question; the next section summarizes the factors that have been used experimentally to augment cell homing and survival.
Targeting Adhesion Molecules: Integrins and Selectins
Adhesion molecules such as selectins and integrins play an essential role in the homing of leukocytes to sites of inflam-mation and of progenitor cells to sites of ischemia. During inflammation, the recruitment of inflammatory cells requires a coordinated sequence of multistep adhesive and signaling events, including selectin-mediated rolling, stimulation by chemokines leading to activation of integrins, integrinmediated firm adhesion on endothelial cell monolayers, diapedesis through the endothelial cell monolayers, and finally migration/invasion in the extracellular matrix involving integrin-dependent processes and matrix-degrading proteases. 13, 35 With respect to progenitor cells, it was shown that selectins are involved in the recruitment of progenitor cells. 36, 37 Interestingly, strategies targeting selectins such as treatment with soluble E-selectin or stimulation of EphB4 receptor by Fc-ephrinB2 were shown to be effective in enhancing the homing of progenitor cells. 36, 38 Interestingly, short-term stimulation of adenosine receptors in EPCs and cardiac endothelial cells rapidly increased EPC adhesion to endothelial cells under static and flow conditions through a PSGL-1/P selectin-dependent pathway. 39 An additional possibility is the ex vivo engineering of progenitor cells. Indeed, ex vivo engineering of CD44 on MSCs converted it into an E-selectin/L-selectin ligand and enhanced the homing capacities of MSCs. 40 In this regard, surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and modifies homing properties. 41 Interestingly, biomaterials such as an acellular collagen-based matrix containing sialyl Lewis(X), which binds L-selectin, increased mobilization, homing, and neovascularization of ischemic limbs through positive effects on endogenous and/or transplanted progenitor cells. 42 The process of rolling is reversible. Many progenitor cells or leukocytes that roll in vivo will not stop but dissociate from the vessel surface and reenter the bloodstream. To stop rolling, the low-affinity rolling interactions of selectins must be replaced by high-affinity adhesion. Thus, the subsequent step of leukocyte homing consists of integrin activation by chemokines and integrin-dependent arrest/firm adhesion of the progenitor cells and leukocytes on the endothelium. 13 An equilibrium of at least 3 different conformations of integrins exists on the cell surface: low-, intermediate-, and highaffinity conformations. Interestingly, ex vivo preactivation of ␤2 integrins in EPCs by an activating antibody increased the homing and neovascularization capacities of human myeloid EPCs in a hind-limb ischemia model. 43 In line with these results, prestimulation with HMGB-1 was shown to stimulate integrin affinity and valency in EPCs and to improve their homing to ischemic tissues, suggesting that ex vivo integrin activation in EPCs is an effective strategy to improve the homing and neovascularization capacities of EPC. 44 Moreover, short-term pharmacological activation of Epac, a guanine nucleotide exchange factor for the small GTPase Rap1 with a cAMP analogon, enhanced integrin-dependent adhesion of myeloid EPCs, CD34 ϩ progenitor cells, and MSCs in vitro and increased the in vivo homing of myeloid EPCs to ischemic tissues and their neovascularization-promoting capacity. 45 In addition, preincubation of EPCs with the adipocytokine leptin increases the adhesive capacity of EPC and their recruitment to neointimal lesions, thereby accelerating reendothelialization and reducing neointima formation. 46 How- 
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Enhancement Strategies for Cardiac Repair ever, the effect of leptin on the homing of progenitor cells to ischemic tissues has not been evaluated so far. Besides homing, integrins directly affect the proliferation, survival, and differentiation of stem/progenitor cells. Indeed, overexpression of tissue transglutaminase, known to support and enhance ␤1 integrin function, increased integrin-dependent adhesion and differentiation of bone marrow-derived MSCs and enhanced their therapeutic potential in a model of myocardial infarction. 47
Enhancing Chemokine/Cytokine/Growth Factor Signaling
Activation by chemokines is an important step for the recruitment of progenitor cells to ischemic tissue. Stromal derived factor-1 (SDF-1; also known as CXCL12) and its receptor CXCR4 are among the most widely studied and are well established to be essential for hematopoietic progenitor cell recruitment and angiogenesis. 48, 49 The expression of SDF-1 is upregulated during acute ischemia 48, 50 and stimulates the CXCR4 receptor, which is expressed on EPCs and BMCs, thereby acting as a chemotactic and promigratory factor. 48 However, in patients with chronic ischemia, the expression of SDF-1 and CXCR4 was significantly suppressed even below the levels detected in control subjects, suggesting a lack of recruitment signals in these patients. 51 Therefore, injection of cytokines may be useful for enhancing progenitor cell recruitment even in the absence of acute ischemia. Indeed, local injection of SDF-1 in ischemic hind limbs increased the recruitment of intravenously infused EPCs, 52, 53 and application of SDF-1 rescued the diabetic impairment of progenitor cell functions in wound healing. 54 Moreover, activation of the tissue by low-energy shock-wave application stimulated the expression of SDF-1 and vascular endothelial growth factor (VEGF) within the target tissue and promoted homing of intravenously infused EPCs. 55 Based on this preclinical study, an ongoing phase I/II study is evaluating the effect of noninvasive low-energy shock-wave pretreatment of the target tissue on BMC recruitment in patients with chronic heart failure (www.clinicaltrials.gov, NCT00326989). Because SDF-1 can be cleaved and thereby inactivated by proteases, Segers et al 56 generated a cleavageresistant SDF-1 by mutating the cleavage site and showed that injection of this stabilized form of SDF-1 further increases progenitor cell recruitment and functional recovery after myocardial ischemia. Inhibition of the dipeptidylpeptidase CD26 after induction of acute myocardial infarction also reduced SDF-1 cleavage, thus leading to enhanced myocardial homing of bone marrow-derived progenitor cells and improved cardiac function. 57 Alternatively, SDF-1 might be brought to the region of interest as piggy back by injected fibroblasts or MSCs that are genetically modified to overexpress and release SDF-1. 52 Interestingly, the effect of SDF-1 seems to be at least partly dependent on heme oxygenase-1. 58 Delivery of heme oxygenase-1 significantly increased VEGF and SDF-1 expression, improved progenitor cell mobilization and homing, and enhanced neovascularization improvement. 59, 60 The appropriate response to SDF-1 and the recruitment of infused or injected progenitor cells depend on the expression of the CXCR4 receptor. 49 Activation of the CXCR4 receptor thus may provide an option to enhance cell recruitment.
Indeed, prestimulation of myeloid EPCs with sphingosine-1phosphate or the synthetic analog FTY720 sensitized CXCR4 signaling and improved blood flow recovery in ischemic hind limbs. 61 Moreover, culture conditions or the buffer used for transporting the cells for cell delivery may affect the expression levels of chemokine receptors. For example, incubation of BMCs with nonbuffered medium and/or plasma reduced the surface expression of CXCR4 and the migratory response toward SDF-1. 62 In contrast, increasing the extracellular calcium concentration stimulated the transcription and surface expression of CXCR4, leading to enhanced recruitment of progenitor cells and augmented neovascularization. 63 Moreover, cultivation of MSCs as 3-dimensional aggregates increased the expression of CXCR4 and enhanced SDF-1induced adhesion to endothelial cell monolayers. 64 Besides SDF-1, other chemokines were shown to be involved in the homing of progenitor cells to ischemic tissues. Indeed, the CXC chemokines interleukin-8/Gro-a and its receptors CXCR2 and CXCR1 contribute to homing of intravenously infused CD34 ϩ progenitor cells to the ischemic myocardium. 65 Local injection of interleukin-8 in the nonischemic myocardium increased the recruitment of CD34 ϩ cells. 65 In addition, blocking CXCR2 inhibited the incorporation of human EPCs expressing CXCR2 at sites of arterial injury. 66 Furthermore, ischemia-induced VEGF acts as a chemoattractant to EPCs. 67 Interestingly, VEGF is sufficient to induce the organ recruitment of bone marrow-derived circulating myeloid cells and their perivascular localization via induction of SDF-1 expression by perivascular cells, suggesting that different cytokines may cooperate during homing of bone marrow cells. 68 In line with these data, overexpression of placenta-derived growth factor and matrix metalloproteinase-9 restored microcirculation and the efficacy of cell therapy in aged dystrophic muscle. 69 In addition, invaded immune competent cells within the ischemic tissue may release further chemokines such as monocyte chemoattractant protein-1 or interleukins that can attract circulating progenitor cells. 70 Besides stimulating migration, monocyte chemoattractant protein-1 and VEGF affect the transendothelial migration of human ex vivo-expanded myeloid EPCs derived from peripheral blood in a ␤2 integrin-dependent manner in vitro. 43 Monocyte chemoattractant protein-1 is also involved in the homing of adult bone marrow-derived MSCs to the ischemic hearts, a process involving the adaptor protein FROUNT, which interacts with the monocyte chemoattractant protein-1 receptor CCR2 and mediates cell polarization. 71 In addition, various growth factors such as IGF, fibroblast growth factor (FGF), and hepatocyte growth factor improve progenitor cell survival and/or function. Local myocardial delivery of IGF-1 with biotinylated peptide nanofibers improved the effect of cell therapy with intramuscularly injected neonatal rat cardiomyocytes after myocardial infarction. 72 Recent evidence also suggests the involvement of the cytokine IGF-2 in the recruitment of progenitor cells to ischemic tissues. 73 Likewise, the IGF-binding protein 3, either locally injected or overexpressed in the injected cells, promotes proper vascular repair after hyperoxic insult mediated by hematopoietic and EPCs. 74 Growth factors also can affect endogenous cardiac stem cells as shown by the combination of IGF-1 and hepatocyte growth factor 75 and the local administration of high-mobility group box protein-1. 76 Finally, the hematopoietic cytokine erythropoietin, currently being tested in several clinical trials, was shown to mobilize EPCs 77 and to stimulate the recruitment and survival of bone marrow-derived progenitor cells to the heart. 78 
Kinases
Downstream of the growth factors, antiapoptotic kinases might be additional attractive targets for improving progenitor cell function. Overexpression of Akt, glycogen synthase kinase, and integrin-linked kinase increased the function of delivered cells, probably also as a result of increased survival. 32, 79 In addition to the prosurvival benefits of the antiapoptotic kinase Akt, overexpression of Akt in MSCs induced an increased expression of paracrine factors such as the secreted frizzled related protein 2, which augments myocardial survival and repair. 80 In addition, activation of AMP-activated protein kinase, which has emerged as an important integrator of signals that control energy balance through the regulation of multiple biochemical pathways, improves EPC function and reendothelialization. 81
Enhancing Cardiac Regeneration
Recent data have challenged the view of the heart as a terminally differentiated organ and provided convincing evidence that new cardiomyocytes can be formed in the adult heart. However, under conditions in which larger numbers of cardiomyocytes are lost, eg, after severe injury or chronic stress, the endogenous regeneration capacity is insufficient to form enough cardiac contractile mass. Cardiac cell therapy therefore aims at physically replacing cardiomyocytes. Alternatively, cell therapy may enhance or reactivate the endogenous regeneration capacity, eg, by paracrine factors stimulating endogenous cardiac stem cells 82 or cardiomyocyte proliferation. Several studies indicate that adult bone marrow-derived progenitor cells are a rich source of cytokines, possibly enhancing the repair after injury in a paracrine manner. These paracrine factors contribute to the reduction of cardiomyocyte death and enhanced neovascularization of the ischemic tissue and may be involved in ameliorating tissue fibrosis. 83 However, the question of whether adult progenitor cells can form a significant functionally meaningful number of new cardiomyocytes is heavily debated. Whereas selected murine c-kit ϩ or human CD34 ϩ bone marrow-derived cells showed a robust engraftment and differentiation of the injected cells in all cardiovascular lineages in some studies, 84, 85 other studies failed to detect cardiac-committed bone marrow-derived cells. 86 Mixed results also were reported when adipose tissue-derived cells were used. 8 Although the local environment was thought to predetermine the cardiac fate of cardiac stem cells and various groups indeed showed a convincing cardiac regeneration capacity of injected cardiac stem cells, 10, 87, 88 others failed to show the formation of a large number of cardiomyocytes. 89 Given that mixed results have been reported for most if not all adult progenitor cells, one may question whether the lack of cardiac regeneration might be caused by technical problems (eg, successful cell injection, cell preparation, and local environment). The opponents, however, may argue that false-positive results were reported because of insufficient controls for the detection of engrafted cells. Although the scientific community is still split with respect to this heated discussion, it appears safe to conclude that it is not easy to drive adult progenitor cells to acquire a cardiac fate and that we do not yet understand the prerequisites and mechanisms of cardiac regeneration. ESCs (and induced pluripotent stem [iPS] cells) that undoubtedly form cardiomyocytes may be an alternative for cell therapy. Although there are several challenges in making ESCs (or induced pluripotent stem [iPS] cells) safely applicable in humans (see earlier discussion), the development of efficient differentiation protocols in vitro allows the use of ESCs as a model system to study the multiple steps and networks regulating cardiac differentiation. The control of these pathways may promote derivation of cardiomyocytes for cell therapy approaches. Moreover, predifferentiation of stem/ progenitor cells may alleviate differentiation of the applied cells to undesired lineages and reduce the risk for uncontrolled proliferation and teratoma formation in the case of ESCs or induced pluripotent stem (iPS) cells.
Several cytokines, growth factors, and small molecules have been shown to promote cardiac differentiation (Tables 1 and 2 90 -123 ). Members of the transforming growth factor-␤ family (transforming growth factor-␤1, 90,91 bone morphogenetic protein-2, 92,93 and bone morphogenetic protein-4 94 -96 ) were among the first identified to increase embryonic and fetal stem cell differentiation to cardiomyocytes (Table 1) .
FGF and IGF-1 also contribute to cardiac differentiation of ESCs, and treatment of cells or target tissue with FGF-2, IGF-1, or a combination of growth factors (FGF-2, IGF-1, and bone morphogenetic protein-2) improved cardiac function in animal models. 72, 124, 125 Of note, as discussed above, these growth factors exhibit a wide range of functions (eg, antiapoptotic activity and proangiogenic effects); thus, it is unclear to what extent the induction of cardiac differentiation contributes to the therapeutic benefits.
Wnts make up another family of growth factors that regulate cardiopoiesis. 126 Individual Wnts either can induce stabilization of ␤-catenin (the so-called canonical Wnts) or can act independently on the classic ␤-catenin pathway. The first evidence of a promotion of cardiac differentiation by Wnts was shown for Wnt-11, one of the noncanonical Wnts required for cardiopoiesis in Xenopus. 127 Subsequent studies reported that Wnt-11 or other noncanonical members of the Wnt family such as Wnt-5a induced or enhanced cardiac gene expression in a variety of adult progenitor cells, including circulating progenitor cells, 101, 104 MSCs, 128 and unfractionated bone marrow-derived cells. 102 The downstream signaling events underlying noncanonical Wnt-induced cardiac gene expression are not entirely clear but include a protein kinase C-dependent pathway. 102, 104 In contrast, the effect of canonical Wnts is rather complex. The activation of ␤-catenin was initially shown to suppress cardiac differentiation during embryonic development, whereas cardiac differentiation was promoted in an in vitro model of a pluripotent mouse cell line. 129 This apparent contradiction was solved by subsequent studies showing that canonical Wnts (such as Wnt-3a) act biphasically and promote cardiac differentiation at early development stages but inhibit it later. 130 As an example, the transcription factor MesP1, which induces cardiovascular differentiation in ESCs, acts by suppressing canonical Wnt signaling. 107 Likewise, the effects of the cardiogenic growth factor IGF-binding protein 4 are mediated via inhibition of noncanonical Wnt signaling. 106 Interestingly, in Isl1 ϩ cardiac progenitor cells and hematopoietic stem cells, canonical Wnts induce prolif- TGF-␤ indicates transforming growth factor-␤; BM, bone marrow; BMP, bone morphogenetic protein; mES, mouse embryonic stem cells; END-2, a visceral endoderm-like cell line; EB, embryoid body formation; OP9, a mouse stromal cell line; DMSO, dimethyl sulfoxide (Me 2 SO); hES, human embryonic stem cells; CM, cardiomyocytes; MSVC, murine stromal vascular cells; and VSEL, very small embryonic stem cell-like cells.
*Coculture with Wnt-11-producing cells using separating membranes. eration, and one may consider using canonical Wnts to expand rare progenitor cell populations. [131] [132] [133] Because endoderm-derived signals are of crucial importance in cardiac development in vivo and drive cardiogenesis of ESCs in vitro, other investigators studied the endodermal secretome to identify factors guiding cardiac differentiation. 134 Based on the findings that secreted factors derived from tumor necrosis factor-␣-primed endoderm enhance cardiac commitment, an ongoing clinical study is addressing whether adult MSCs cultured with endoderm-derived factors improve cardiac function in patients with heart failure (C-Cure Trial, www.clinicaltrials.gov, NCT00810238).
Notch receptors and their cognate ligands transduce crucial signals between cells and are essential for cardiovascular development. 135 Although Notch signaling was initially considered to block cardiac differentiation during embryonic development, several recent studies have demonstrated that Notch is required for cardiac gene expression in circulating progenitor cells 109 and in Isl1 ϩ cardiac progenitor cells. 136 Notch additionally redirects hemangioblasts to a cardiac fate. 137 Consistently, activation of Notch improved hemodynamic functions of infarcted hearts, 138 but the therapeutic benefits may also be caused by other functions of Notch independently of its putative effect on progenitor cells.
Besides growth factors and cell-to-cell communication signaling pathways, small molecules or peptides are attractive candidates for inducing cardiac differentiation ( Table 2 ). In addition to the well-known inducers of cardiac differentiation such as the DNA-demethylating substance 5-azacytidine or dimethyl sulfoxide, the peptide hormone oxytocin was shown to induce cardiac gene expression in PC19 cells and cardiac stem cells (Table 2 ). In addition, chemical library screens revealed new candidates to enhance cardiac differentiation such as vitamin C 112 or the family of sulfonyl hydrazone small molecules that can trigger cardiac mRNA and protein expression in a variety of embryonic and adult stem/progenitor cells. 113 Pretreatment of granulocyte colony-stimulating factor-mobilized mononuclear cells with sulfonyl hydrazone augmented cell engraftment and recovery after myocardial ischemia. 113 Finally, one should not neglect the influence of physical stimuli (for review, see the work by Heng et al 139 ). Mechanical activation of adult bone marrow-derived progenitor cells by exposure to oscillation stretch increased cardiac gene expression. Moreover, electric stimulation influences ESC differentiation.
In summary, several factors and strategies have been identified to augment cardiac differentiation. Some of the factors also were shown to improve recovery after myocardial infarction, although in most if not all cases it is difficult to discriminate between the effects on homing, survival, and paracrine activity of the injected cells compared with effects on cardiac differentiation. Most of the signals controlling cardiac embryonic development act in a context-and timedependent manner, suggesting that although it might be possible to sensitize or facilitate progenitor cell differentiation before implantation into the myocardium (where cells are exposed to cardiomyogenic signals), the induction of full cardiac differentiation and maturation of progenitor cells in vitro may need a well-controlled and possibly multiphasic treatment with different substances/scaffolds in a tissue engineering approach. The selection of cardiac-committed cells from embryonic bodies generated by ESCs or induced pluripotent stem (iPS) cells may provide an alternative.
Outlook
Although cell therapy is a rather new (some may say immature) discipline, ample new information has been obtained during the last 8 years that opens many possibilities for future studies. The successful further development of cell therapeutic strategies, however, requires a close interaction between physician-scientists and basic researchers. Although cautious persons may argue that we first have to fully understand the biology of cell therapy and the mechanisms underlying the putative benefits before pursuing further clinical studies, the field of cell therapy, more than any other field, needs translational studies and a close forward-andreverse interaction between bench and bedside. Why is this the case? First, for any clinical trial in the near future, human cells and often autologous cells will be applied. Because age and disease affect progenitor cells, preclinical studies with patient-derived cells are mandatory. In addition, to study the biological function of human cells, immunodeficient or immune-suppressed animals have to be used. Given the importance of the immune system and inflammation for healing, neovascularization, and fibrosis, this is a major limitation that deserves to be considered carefully. Although there has been some experience with allogeneic cells in hematology, the development of animal models to preclinically confirm the safety of allogeneic cells for cardiac regeneration is challenging. Second, homing and engraftment not only are regulated by multiple biological signaling cascades but also may be critically affected by the delivery device and by the patient's underlying disease. For example, the cardiac microenvironment in a patient with acute myocardial infarction is entirely different from a healed scar of a patient with end-stage heart failure, and this likely will be of relevance when choosing the optimal cell therapy. It might well be that specific disease states require different cell types and tailored cell delivery strategies. All of this requires close interaction between representatives from different scientific disciplines such as cell biologists, chemists, engineers, and physicians to make cell therapy a success in the long term.
